Bellus licenses Kiacta drug to Celtic

Bellus Health (TSX:BLU) has agreed to license the worldwide rights of its Kiacta drug to Celtic Therapeutics for upfront payments of $10 million (U.S.), with $5 million to be paid on closing and the balance in six months. Celtic, a global private equity firm, will finance and complete a Phase 3 clinical trial of Kiacta, [...]

Protox lands licensing deal in Japan

Protox Therapeutics (TSX:PRX) has signed a potential $75 million (U.S.) licence agreement with Kissei Pharmaceutical to develop and commercialize Protox’s PRX302 drug in Japan for the treatment of enlarged prostate, prostate cancer and other diseases of the prostate. Under the accord, Protox will receive an upfront payment of $3 million and is eligible to receive [...]

Analysts cut Labopharm price targets on marketing deal

After weighing the pros and cons of Labopharm’s joint venture marketing accord with Italy’s Gruppo Angelini, Dundee Securities and Versant Partners cut their price targets on “buy-rated” Labopharm (TSX: DDS; NASDAQ: DDSS), with Dundee moving the target down to $2.40 from $3 and Versant down to $2.50 from $3. Dundee analyst David Martin cited “increased [...]

Sernova to raise $1.2 million in private placement

Sernova (TSX-V:SVA) is offering up to eight million units at a price of 15 cents each to raise up to $1.2 million in a non-brokered private placement and has completed the first closing under the offering, raising $405,250 through the sale of 2,701,666 units. Each unit consists of one common share and one-half of a [...]

Cormark ups Cardiome price target

Cormark Securities has raised its price target on “buy-rated” Cardiome Pharma (TSX:COM; NASDAQ:CRME) to $10.50 from $7.50, citing a positive outlook from several catalysts expected this year.  The stock closed at $8.28 on Tuesday. According to analyst David Dean, those catalysts included European approval in mid-2010 of the IV version of Cardiome’s vernakalant drug to [...]

Versant ups Patheon to buy

Versant Partners upgraded Patheon (TSX:PTI) to “buy” from “neutral” and raised the 12-month target price to $3.60 from $3.25. The stock is trading at $2.62, down one cent, on Tuesday afternoon. Analyst Doug Loe writes that in addition to Patheon closing a $280 million (U.S.) offering of notes, there are “encouraging signs from peers that [...]

In conversation with Marc Létourneau

Marc Létourneau is very well known among the senior management and boards of directors of many emerging growth companies.  An accomplished investment banker with over 20 years of experience providing strategic advice, raising capital and negotiating mergers and acquisitions in both domestic and international markets, he has played a key role in shaping the current [...]

Opmedic to build new centre in Montreal

Opmedic Group (TSX:OMG) plans to build a new surgical and endoscopic centre on the South Shore of Montreal, which will have two operating rooms, one for day surgeries and one for endoscopy.  It will increase the number of operating rooms in Opmedic’s surgical business unit by over 25%, bringing the total number of surgical and [...]

IntelGenx to license anti-migraine film product

IntelGenx (TSX-V:IGX) has signed a binding term-sheet with closely held RedHill Biopharma of Israel to co-develop and license IntelGenx’s rapidly dissolving anti-migraine oral film product based on its VersaFilm technology. “We are excited to have concluded our first, of what we believe to be many future, thin film partnerships,” CEO Dr. Horst Zerbe said in [...]

Cangene to begin distributing WinRho in the U.S.

Cangene (TSX:CNJ) will assume the U.S. distribution of its WinRho SDF on June 1, 2010 from Baxter Healthcare, which had been selling the immune globulin IV product since March, 2005. “This move is in line with our increasing focus on our commercial products, particularly in the important U.S. market,” Cangene CEO Dr. John Langstaff said [...]

Next Page »